Physician profile
Tauseef Qureshi
NPI 1649471319
$5,442.10
in general payments reported to CMS, 2019-2025
24 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $430 · 2021: $51.80 · 2022: $3,321 · 2023: $412 · 2024: $420 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,187.29 | 2020-2023 | |
| Glaxosmithkline, LLC. | $428.05 | 2019-2024 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $272.93 | 2022-2025 | |
| Eko Health, INC. | $249.00 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $163.27 | 2019-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.77 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Genentech USA, INC. | $137.82 | 2019-2020 | |
| Allergan, INC. | $106.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $96.50 | 2019-2020 | |
| Inari Medical, INC. | $86.54 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $68.51 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $65.34 | 2020-2021 | |
| Baxter Healthcare | $63.06 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Kestra Medical Technology Services, INC. | $54.02 | 2025 | Assure Wcd |
| Zoll Respicardia, INC. | $47.67 | 2024 | Remede System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $44.37 | 2023 | Tyvaso |
| Pulmonx Corporation | $41.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.47 | 2019-2023 | |
| Philips North America LLC | $35.34 | 2022-2023 | |
| Grifols USA, LLC | $26.78 | 2022 | |
| Chiesi USA, INC. | $24.55 | 2023 | Cleviprex |
| Vifor Pharma, INC. | $24.11 | 2024 | Zemaira |
| Inspire Medical Systems, INC. | $17.62 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $16.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tauseef Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.